DSE:PHARMAID

Pharma Aids Limited research

Reports on Pharma Aids Limited

Company · Analysis · 31 Oct 2026

Pharma Aids: FY2025 net sales of BDT 438m, 9M FY2026 sales up 17.6% and profit up 28.1%, sponsors at 19.38%

Bangladesh's listed maker of neutral glass ampoules for drug companies: seven years of filings, a 30.3% gross margin, BDT 27.3m of borrowings at June 2025, an auditor's opinion worded 'except for', and FY2026 results due to the board on 3-Nov-2026.

Pharma Aids Limited makes one product family: neutral glass ampoules, the small sealed glass containers that injectable medicines are filled into. It sells all of its output to pharmaceutical companies in Bangladesh in local currency and does not export; its main raw materials, neutral glass…

Peer comparisons and industry research covering Pharma Aids Limited

Company · DSE:IBP · Pharmaceuticals & healthcare · Analysis · 31 Oct 2026

Indo-Bangla Pharmaceuticals: revenue of BDT 184.2m in FY2025 against BDT 866.1m in FY2020, a qualified audit with a going-concern paragraph, and 9M FY2026 profit of BDT 2.8m

The Barishal-based tablet and capsule maker reported net losses of BDT 41.0m in FY2024 and BDT 36.8m in FY2025. Its auditor qualified the FY2025 accounts on four bases and reported a material uncertainty on going concern. Nine-month FY2026 revenue was BDT 134.8m, against BDT 76.9m a year earlier.

Indo-Bangla Pharmaceuticals PLC (IBP) makes and sells human-health medicines, excluding antibiotics, from a single factory at College Road, Barishal. The business traces to Indo-Pak Pharmaceutical Works, founded in 1954; it was privatised in 1982, incorporated as a private limited company on 18-Jun-2014, converted to a…

All Bangladesh research →